By HotStockRockets | Saturday 30 April 2016
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Optibiotix (OPTI) will be presenting on both the main stage and in a breakout room at UK Investor today!. The mood in the camp is incredibly upbeat and we hope you grab a chance to chat to CEO O'Hara to see why.
Results the other day, for the year to November 30 2015, showed a loss of £1.3 million but cash as at today is £4 million so there is no balance sheet worry.
The company stresses achievements of last year including, a substantive increase in the IP portfolio, five to eleven patents, three to eight strain registrations, three to seven trademarks, human and manufacturing studies on the cholesterol supplement successfully completed, Formation of a Scientific Advisory Group composed of international key opinion leaders and the signing of four commercial agreements with Nizo, Venture Life, CSL and a large US multinational. Whatever.
The national press has this week been gushing about the potential of this company in tackling obesity, diabetes etc ( Times, Mail, Express) and talking of big sales soon. that is they key. Will O'Hara announce deals which give actual numbers showing the monetisable potential here. If so the shares should move fast.
There seems to be a persistent quasi institutional seller at around 80p. The word we hear is that he will be cleared out by next week and if that happens the shares will race on any news.
We expect that news soon so if you can buy at 80p or below we advise doing so right now.
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |